Trial Profile

Clinical Study of SHR1701 in Combination With CAPOX and SHR2554 or Apatinib for First-line Treatment of Advanced Gastric Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Retlirafusp alfa (Primary) ; Rivoceranib (Primary) ; Zeprumetostat (Primary) ; Capecitabine; Oxaliplatin
Indications Adenocarcinoma; Gastric cancer
Focus Therapeutic Use

Most Recent Events

16 Apr 2026 Protocol amended to change number of arms from 1 to 2, patient number increased, Rivoceranib added to experimental arm.
16 Apr 2026 Planned number of patients changed from 36 to 78.
26 Dec 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com